English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Nowadays multiple brain metastases (up to 10–15 tumors) are treated with SRS alone. The most common diagnosis-specific Graded Prognostic Assessment and Score for Radiosurgery indices are based on data regarding limited brain metastases (1–4). Moreover, many of patients included in that analyses were treated with WBRT or combination of WBRT and SRS and some relevant data were not included due to a retrospective analysis of large datasets. SRS may increase intracranial control of disease, however, treatment of patients with a prognosis of fewer than 3 months survival after SRS may not be clinically reliable. Therefore we conducted an analysis of prospective registry to find the factors that correlate with very short survival after SRS. Materials and methods, A consecutive cohort of 84 patients treated with SRS only for brain metastases between 04.2018-03.2019. Data prospectively collected and introduced into a registry of patients treated with SRS in our department were analyzed. The analyzed factors are age, primary site, histopathology, previous surgery, molecular results, systemic therapy, duration of SRS planning, the extent of extracerebral metastatic disease, number of brain metastases, mass effect and neurological symptoms/ We performed a univariate analysis and multivariate Cox regression model to find a correlation between clinical and molecular data and survival in brain metastases patients treated with SRS only. Factors predicted early death and correlated with survival will be presented at the conference

RADI-01. PROGNOSTIC FACTORS OF SHORT SURVIVAL FOR BRAIN METASTASES TREATED WITH SRS WITHOUT WBRT.